Flk1 Deficiency and Hypoxia Synergistically Promote Endothelial Dysfunction, Vascular Remodeling, and Pulmonary Hypertension

BACKGROUND: The mechanisms underlying pulmonary hypertension (PH) remain largely unknown; further, why advanced vascular remodeling preferentially occurs in arterioles is yet to be answered. VEGF (vascular endothelial growth factor) regulates angiogenesis through Flk1 (fetal liver kinase 1) and Flt1 (fms-like tyrosine kinase 1) on endothelial cells (ECs), which may be related to PH pathogenesis. However, spatiotemporal expression patterns of Flk1 and Flt1 in the pulmonary vascular system and the role of endothelial Flk1 in PH development remain poorly understood. METHODS: We analyzed multiple reporter mice, including Flk1-GFP (green fluorescent protein) bacterial artificial chromosome transgenic (Tg), Flt1-DsRed bacterial artificial chromosome Tg, and Flk1-GFP/Flt1-DsRed double Tg mice, to determine the spatiotemporal expression of Flk1 and Flt1 in hypoxia-induced PH. We also used Cdh5CreERT2/Flk1f/f/Tomato (Flk1-KO [knockout]) mice to induce EC-specific Flk1 deletion and lineage tracing in chronic hypoxia. RESULTS: Flk1 was specifically expressed in the ECs of small pulmonary vessels, including arterioles. Conversely, Flt1 was more broadly expressed in the ECs of large- to small-sized vessels in adult mouse lungs. Intriguingly, Flk1+ ECs were transiently increased in hypoxia with proliferation, whereas Flt1 expression was unchanged. Flk1-KO mice did not exhibit pulmonary vascular remodeling nor PH in normoxia; however, the arteriolar ECs changed to a cuboidal shape with protrusion. In hypoxia, Flk1 deletion exacerbated EC dysfunction and reduced their number via apoptosis. Additionally, Flk1 deletion promoted medial thickening and neointimal formation in arterioles and worsened PH. Mechanistically, lineage tracing revealed that neointimal cells were derived from Flk1-KO ECs. Moreover, RNA sequencing in pulmonary ECs demonstrated that Flk1 deletion and hypoxia synergistically activated multiple pathways, including cell cycle, senescence/apoptosis, and cytokine/growth factor, concomitant with suppression of cell adhesion and angiogenesis, to promote vascular remodeling. CONCLUSIONS: Flk1 and Flt1 were differentially expressed in pulmonary ECs. Flk1 deficiency and hypoxia jointly dysregulated arteriolar ECs to promote vascular remodeling. Thus, dysfunction of Flk1+ ECs may contribute to the pathogenesis of advanced vascular remodeling in pulmonary arterioles.

[1]  M. Humbert,et al.  2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. , 2022, European heart journal.

[2]  B. Cockrill,et al.  Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. , 2022, JAMA.

[3]  S. Guttentag,et al.  A single-cell atlas of mouse lung development. , 2021, Development.

[4]  J. Cortijo,et al.  Senescence Alterations in Pulmonary Hypertension , 2021, Cells.

[5]  I. Komuro,et al.  Three-Dimensional Visualization of Hypoxia-Induced Pulmonary Vascular Remodeling in Mice. , 2021, Circulation.

[6]  T. Helbich,et al.  Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension , 2020, Basic Research in Cardiology.

[7]  P. Ainslie,et al.  Global Reach 2018 Heightened α-Adrenergic Signaling Impairs Endothelial Function During Chronic Exposure to Hypobaric Hypoxia , 2020, Circulation research.

[8]  M. Humbert,et al.  Familial pulmonary arterial hypertension by KDR heterozygous loss of function , 2020, European Respiratory Journal.

[9]  W. Chung,et al.  Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension , 2019, bioRxiv.

[10]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[11]  Denis Torre,et al.  BioJupies: Automated Generation of Interactive Notebooks for RNA-Seq Data Analysis in the Cloud. , 2018, Cell systems.

[12]  A. Ntokou,et al.  Cell Autonomous and Non-cell Autonomous Regulation of SMC Progenitors in Pulmonary Hypertension , 2018, Cell reports.

[13]  Emma Gordon,et al.  Mechanisms and regulation of endothelial VEGF receptor signalling , 2016, Nature Reviews Molecular Cell Biology.

[14]  M. Cosio,et al.  Destructive index: a measurement of lung parenchymal destruction in smokers. , 2015, The American review of respiratory disease.

[15]  Takeshi Miyamoto,et al.  Neurons Limit Angiogenesis by Titrating VEGF in Retina , 2014, Cell.

[16]  N. Voelkel,et al.  The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. , 2014, American journal of respiratory cell and molecular biology.

[17]  Satoru Takahashi,et al.  Study of normal and pathological blood vessel morphogenesis in Flt1‐tdsRed BAC Tg mice , 2012, Genesis.

[18]  Satoru Takahashi,et al.  Flk1-GFP BAC Tg mice: an animal model for the study of blood vessel development. , 2010, Experimental animals.

[19]  Thomas Colatsky,et al.  Biomarkers of Endothelial Cell Activation Serve as Potential Surrogate Markers for Drug-induced Vascular Injury , 2010, Toxicologic pathology.

[20]  F. Jaisser,et al.  Tamoxifen administration routes and dosage for inducible Cre-mediated gene disruption in mouse hearts , 2010, Transgenic Research.

[21]  N. Voelkel,et al.  Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension , 2010, Circulation.

[22]  A. Barberis,et al.  Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis , 2010, Nature.

[23]  Allan R. Jones,et al.  A robust and high-throughput Cre reporting and characterization system for the whole mouse brain , 2009, Nature Neuroscience.

[24]  P. Escobar,et al.  Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer. , 2009, Gynecologic oncology.

[25]  R. Adams,et al.  DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. , 2009, Blood.

[26]  Zev Rosenwaks,et al.  Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. , 2009, Cell stem cell.

[27]  Christopher C W Hughes,et al.  Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. , 2008, Circulation research.

[28]  N. Voelkel,et al.  Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. , 2007, American journal of respiratory and critical care medicine.

[29]  N. Denis,et al.  Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate , 2007, Oncogene.

[30]  N. Voelkel,et al.  Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats , 2007, Circulation research.

[31]  M. Brielmeier,et al.  Optimization of spatiotemporal gene inactivation in mouse heart by oral application of tamoxifen citrate , 2007, Genesis.

[32]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  N. Voelkel,et al.  Initial apoptosis is followed by increased proliferation of apoptosis‐resistant endothelial cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  P. Yue,et al.  SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. , 2004, Journal of hepatology.

[35]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[36]  P. McLoughlin,et al.  Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation , 2003, The Journal of physiology.

[37]  P. Hirth,et al.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  S. Eddahibi,et al.  Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. , 2000, American journal of respiratory cell and molecular biology.

[39]  J. Laaban,et al.  Pulmonary arterial hypertension in patients with sleep apnoea syndrome , 2000, Thorax.

[40]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[41]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[42]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[43]  A. Nadas,et al.  Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. , 1979, The American journal of physiology.

[44]  M. Dunnill Quantitative Methods in the Study of Pulmonary Pathology , 1962, Thorax.

[45]  K. Fukuda,et al.  Distinct expression patterns of Flk1 and Flt1 in the coronary vascular system during development and after myocardial infarction. , 2018, Biochemical and biophysical research communications.

[46]  Lucy Fairclough,et al.  Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease , 2009, Respiratory research.

[47]  M. Rabinovitch Molecular pathogenesis of pulmonary arterial hypertension. , 2008, The Journal of clinical investigation.

[48]  M. Shibuya,et al.  Structure and function of vascular endothelial growth factor receptor-1 and -2. , 1999, Current topics in microbiology and immunology.